GlassScriptPhysician profile
Tahereh Jamshidi
NPI 1225201916
$9,918.49
in general payments reported to CMS, 2019-2025
20 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $1,177 · 2021: $3,088 · 2022: $1,654 · 2023: $779 · 2024: $2,754 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,408 · Food and Beverage: $1,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,407.50 |
| Food and Beverage | $1,244.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $2,880.86 | 2021-2023 | Lupkynis |
| Sobi, INC | $2,582.74 | 2024 | |
| Horizon Therapeutics Plc | $1,396.96 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $774.98 | 2022 | |
| Amgen INC. | $528.22 | 2019-2024 | Otezla, Enbrel, Tavneos |
| Novartis Pharmaceuticals Corporation | $324.81 | 2019-2023 | |
| Glaxosmithkline, LLC. | $218.91 | 2019-2023 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals LP | $216.17 | 2022-2023 | Saphnelo |
| Ucb, INC. | $203.23 | 2021-2024 | Cimzia |
| Abbvie INC. | $178.76 | 2020-2022 | |
| Janssen Biotech, INC. | $133.18 | 2021-2023 | Simponi Aria |
| Genzyme Corporation | $118.75 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $112.10 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $79.74 | 2021 | |
| Genentech USA, INC. | $40.69 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $39.81 | 2022-2023 | Strensiq |
| Merck Sharp & Dohme LLC | $26.89 | 2019 | |
| Mallinckrodt Enterprises LLC | $23.85 | 2019 | |
| Csl Behring | $20.24 | 2019 | |
| Hikma Pharmaceuticals USA | $17.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tahereh Jamshidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.